Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.

...
more >
Latest Newsmore >
09/06/17
CORRECTING and REPLACING -- Advanced Accelerator Applications S.A.
SAINT-GENIS-POUILLY, France, Sept. 06, 2017 (GLOBE NEWSWIRE) -- In a release issued earlier today by Advanced Accelerator Applications S.A. (NASDAQ:AAAP), please note that the headline has been updated to omit FUJIFILM RI Pharma, Co., LTD. The corrected headline and release follows: Advanced Accelerator Applications Announces First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera®) Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an inter... 
09/06/17
Advanced Accelerator Applications and FUJIFILM RI Pharma, Co., LTD Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera®)
SAINT-GENIS-POUILLY, France, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the first patient has been treated in a Phase I clinical study of lutetium Lu 177 dotatate* in patients with inoperable, somatostatin receptor positive, progressive pancreatic, gastrointestinal, or pulmonary neuroendocrine tumors (NETs) in Japan. The primary objective o... 
08/31/17
Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017
Positive CHMP Opinion for Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETS FDA Acknowledged Receipt and Completeness of NDA Resubmission for Lutetium Lu 177 Dotatate* (Lutathera®) and Provided PDUFA Date of January 26, 2018 Second Quarter 2017 Highlights: Sales for the second quarter of 2017 increased 32% compared to the second quarter of 2016 NETSPOT® unit sales per month increased 63% (from 562 to 915) from March to June 2017 Received positive opinion for lutetium Lu 177 dota... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources